MEDI5752 (volrustomig), a novel PD-1/CTLA-4 bispecific antibody, in the first-line (1L) treatment of 65 patients (pts) with advanced clear cell renal cell carcinoma (aRCC)

MH Voss, B Garmezy, SH Kim, JP Maroto Rey, AB Mansinho, A Rodriguez-Vida, J Oliveira, M van Dongen, L Medina Rodriguez, S Negrier, B Tran, BA Carneiro, E Castanon Alvarez, SY Rha, Y Wang, SD Gainer, Z Tang, I Achour, JM Asare, L Albiges